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Background: Chronic kidney disease (CKD) is associatedwith poor outcomes after percutaneous coronary
intervention (PCI). The aim of the studywas to compare zotarolimus- and everolimus-eluting stents used
during primary PCI in patients with acute myocardial infarction (AMI) and CKD.
Methods:Weselected854 consecutive ST-elevationMIpatientswithCKD (estimatedglomerularﬁltration
rate <60mL/min/1.73m2) undergoing primary PCI who were followed up for 12 months. They were
divided into two groups based on type of stents implanted: (1) zotarolimus-eluting stent (ZES) and (2)
everolimus-eluting stent (EES). The study end point was the 12-month major adverse cardiac events
(MACE) which included all-cause death, non-fatal MI, target lesion revascularization (TLR), and target
vessel revascularization (TVR).
Results: The average number of stents used per vessel was 1.4±0.7. A total of 433 patients received ZES
and 421 patients received EES. There was no signiﬁcant difference in the incidence of 12-month MI,
TLR, or TVR. All-cause death was found to be borderline signiﬁcant between two groups (2.8% in ZES vs
0.9% in EES, p=0.05). The incidence of 12-month MACE in ZES and EES was 5.7% and 2.6% respectively,
p=0.022. Stent thrombosis did not differ between groups (p=0.677). Kaplan–Meier analysis did not show
signiﬁcant difference for 12-monthMACE-free survival between groups (log-rank p=0.158). It remained
the same even after propensity adjustment for multiple confounders in Cox model (p=0.326).
Conclusions: Implantation of ZES or EES provided comparable clinical outcomes with similar risk of 12-
month MACE and death in STEMI patients with CKD undergoing primary PCI.
© 2014 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.∗ Corresponding author at: Professor, Principal Investigator of Korea Acute
yocardial Infarction Registry, Chonnam National University Hospital, 671 Jaebon-
ro, Dong-gu, Gwangju 501-757, Republic of Korea. Tel.: +82 62 220 6243;
ax: +82 62 228 7174.
E-mail addresses: myungho@chollian.net, myungho@chol.com (M.H. Jeong).
ttp://dx.doi.org/10.1016/j.jjcc.2014.02.002
914-5087/© 2014 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.Introduction
Patients with chronic kidney disease (CKD) present with
accelerated atherosclerosis and higher cardiovascular morbid-
ity and mortality [1–3]. Furthermore, CKD is associated with
adverse outcome following percutaneous coronary intervention
(PCI) [4,5], likely related to endothelial dysfunction, inﬂammation,
and platelet activation. After PCI with bare metal stents (BMS), the
need for repeat revascularization remains high [6], although the
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estenosis rate inmild tomoderateCKD isnot increasedat9months
7]. Retrospective analyses have demonstrated that, in the interme-
iate term, despite a higher overall mortality and morbidity after
CI, patients with end-stage renal disease [8] as well as those with
ilder degrees of CKD [9] beneﬁt from lower rates of target vessel
evascularization (TVR) with drug-eluting stent (DES) versus BMS
lacement. Despite the high prevalence of coronary artery disease
mong CKD patients, this patient population has been consistently
xcluded from the major clinical trials in cardiovascular medicine
10].
We sought to investigate which of the most commonly used
tents best suit patients with moderate to severe CKD undergoing
rimary PCI. We compared 12-month the clinical outcomes in two
ypes of stents.
ethods
This is a retrospective study that was carried out in the Heart
enter of Chonnam National University Hospital, Gwangju, Korea.
he permission to carry out the study was obtained from the
ospital authorities (Institutional Review Board number 05-49, I-
008-01-009) and written informed consent was taken from all
atients.
orea Acute Myocardial Infarction Registry
The Korea AcuteMyocardial Infarction Registry is a prospective,
ulticenter, observational registry designed to examine current
pidemiology in hospitalmanagement and the outcome of patients
ith acutemyocardial infarction (AMI) in Korea for the commemo-
ationof the50th anniversary of theKoreanCirculation Society. The
egistry included 52 community and university hospitals for pri-
ary PCIwith 1-year clinical follow-up.Datawere collected at each
ite by a well-trained study coordinator based on a standardized
rotocol [11].
tudy population
Patients were enrolled in the registry after admission to
articipating hospitals with a suspected diagnosis of AMI.
atients’ medical documents were used to note the demo-
raphic data, clinical characteristics, and relevant laboratory
esults.
A total of 854 consecutive patients with ST-segment ele-
ation MI with CKD undergoing primary PCI from April 2006
hrough September 2010 were selected in this study. We
tudied their 12-month clinical outcomes (follow-up rate was
00%). CKD was deﬁned as estimated glomerular ﬁltration rate
eGFR) <60mL/min/1.73m2 calculated using the Modiﬁcation
f Diet in Renal Disease (MDRD) method [12]. Patients on
emodialysis or continuous ambulatory peritoneal dialysis, with
ardiogenic shock and evidence of heart failure were excluded
rom this study. They were divided into two groups based on
he type of stents implanted – zotarolimus-eluting stents (ZES,
= 433, endeavor =369 and resolute =64; Medtronic CardioVas-
ular, Santa Rosa, CA, USA), and everolimus-eluting stents (EES,
= 421).
eﬁnitions and clinical endpoints
A ﬁnal diagnosis of AMI was made according to the Euro-
ean Society of Cardiology/American College of Cardiology (ACC)
iagnostic criteria of AMI [13]. Hypertension was deﬁned as
ystolic blood pressure >140mmHg and/or diastolic blood pres-
ure >90mmHg at rest, at repeated measurements or treatmentology 64 (2014) 273–278
with anti-hypertensive medications. Diabetes was deﬁned as hav-
ing an established diagnosis of diabetes mellitus or use of oral
hypoglycemic agent or insulin to lowerbloodglucose levels.Hyper-
lipidemia was deﬁned as a total cholesterol level >200mg/dL or
treatmentwith a lipid-lowering agent. Coronary artery diseasewas
deﬁnedashistoryofMI, revascularizationprocedure, or obstructive
coronary artery disease.
Peripheral blood samples were obtained using direct venipunc-
ture. Blood samples were centrifuged and serum was removed
and stored at a temperature of −70 ◦C until the assay could
be performed for proteins and sugar. Absolute creatine kinase-
MB levels were determined by radioimmunoassay (Dade Behring,
Inc., Miami, FL, USA). Cardiac speciﬁc troponin I levels were
measured by a paramagnetic particle, chemiluminescent immu-
noenzymatic assay (Beckham, Coulter, Inc., Fullerton, CA, USA).
Twelve-hour fasting serum levels of total cholesterol, triglyc-
eride, and low- and high-density lipoprotein cholesterol were
measured by standard enzymatic methods. Blood samples for
high-sensitivity C-reactive protein (CRP) were obtained on admis-
sion and analyzed turbidimetrically with sheep antibodies against
human CRP; this has been validated against the Dade Behring
method.
Two-dimensional echocardiography was performed in all
patients and left ventricular ejection fraction was assessed using
modiﬁed Simpson’s biplanar method. The morphology in coro-
nary angiography was classiﬁed according to the criteria of
ACC/American Heart Association (AHA) [14]. Degree of coronary
ﬂowwas classiﬁed by Thrombolysis InMyocardial Infarction (TIMI)
score [15]. Renal function was assessed by eGFR, which was
calculated using the MDRD method [12]. teh presence of left
main coronary artery stenosis was deﬁned as a luminal steno-
sis ≥50%. Multivessel disease was deﬁned as the presence of
a lesion with >50% diameter stenosis in a non-infarct related
coronary artery. Successful PCI was deﬁned as TIMI ﬂow three
with residual stenosis ≤50% in the infarct-related artery. In-
hospital complications included any of atrio-ventricular block,
bradycardia, ventricular tachycardia/ventricular ﬁbrillation, atrial
ﬁbrillation, cardiogenic shock, no re-ﬂow, dissection, acute renal
failure, metabolic acidosis/lactic acidosis, cerebrovascular event,
or infection/sepsis. All patients were administered loading doses
of aspirin 325mg and clopidogrel 300–600mg before PCI. Anti-
coagulation during PCI was performed according to the routine
practices of each hospital. After the procedure, aspirin 100–300mg
(once per day) was prescribed indeﬁnitely. Clopidogrel was pre-
scribed continuously for 1 year to patients who underwent DES
implantation.
The clinical endpoint of this studywas themajor adverse cardiac
events (MACE) which included all-cause death, non-fatal myocar-
dial infarction (MI), target lesion revascularization (TLR) and TVR
during the 12-month follow-up. Non-fatal MI was deﬁned as the
presence of clinical symptoms, electrocardiographic change, or
abnormal imaging ﬁndings of MI combined with an increase in
creatine kinase-MB fraction or troponin T/I more than the 99th
percentile of the upper normal limit that was not related to an
interventional procedure. TVR deﬁned as clinically driven repeat
revascularization of a lesion in the same epicardial vessel treated
in the index procedure at 12-month follow-up. TLR was deﬁned
as any revascularization of the target lesion due to restenosis or
re-occlusion within 5mm proximal/distal to the stent. All data
were recorded on a standardized, electronic, web-based registry
at http://www.kamir.or.kr.Statistical analysis
SPSS 17.0 for windows (SPSS, Inc., Chicago, IL, USA) was
used for all analysis. Continuous variables were presented as
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ean± standard deviation; comparisons were conducted by Stu-
ent’s t-test. Discrete variables were presented as percentages
nd frequencies; comparisons were conducted by chi-square
tatistics. A p-value <0.05 was considered statistically signiﬁcant.
aplan–Meier curveswere constructed to examine the incidence of
linical endpoints. Coxproportional hazard analysiswasperformed
o identify amodelwith independent predictive factorswith deter-
ination of a hazard ratio and its 95% conﬁdence interval for each
ariable in the model. Covariates included in the model were age,
tent length, pre-procedure TIMI ﬂow grade 0, creatinine kinase-
B, and the use of thrombus aspiration device. As the number of
2-month MACE was relatively small in our study population, we
imited the variables into the model. The results are presented as
djusted hazard ratios with 95% conﬁdence intervals and p-values.
e performed propensity score matching to enable an even more
igorous adjustment for selection biases and confounding factors.
esults
A total of 854 consecutive patients with AMI and CKD undergo-
ng PCI were included in the present study. The average age of the
otal population was 64.1±12.7 years and 81.6% were men. The
ean stent length was 23.0±6.5mm and the mean stent diame-
er was 3.2±0.5mm. The average number of stents used per vessel
as 1.4±0.7.
able 1
aseline clinical and laboratory characteristics, and concomitant medications.
Variable ZES
n=433
Age (years) 66.3±13.4
Male gender 346 (79.9)
Systolic blood pressure (mmHg) 123.8±29.9
Heart rate (beats/min) 72.5±18.8
Left ventricular ejection fraction (%) 52.3±17.2
Killip class >1 138 (31.9)
Hypertension 227 (52.4)
Diabetes mellitus 111 (25.6)
Previous history of coronary artery disease 42 (9.7)
Family history of coronary artery disease 45 (10.4)
Smoking history 268 (61.9)
Hyperlipidemia 53 (12.2)
Laboratory characteristics
Glucose (mg/dL) 175.9±75.3
Creatinine (mg/dL) 1.5±1.4
Total cholesterol (mg/dL) 180.0±40.8
Triglyceride (mg/dL) 125.0±79.9
HDL-C (mg/dL) 43.2±16.1
LDL-C (mg/dL) 112.5±35.6
hsCRP (mg/dL) 4.2±13.8
NT-pro-BNP (pg/mL) 3784.1±7772.3
HbA1C (%) 6.5±1.4
Max.CK-MB (U/L) 211.8±357.3
Troponin-I (ng/mL) 64.9±111.9
Discharge medication
Aspirin 410 (94.7)
Clopidogrel 411 (94.9)
Cliostazol 110 (25.4)
Calcium channel blocker 10 (2.3)
Beta blocker 341 (78.7)
ACE inhibitor 253 (58.4)
Angiotensin receptor blocker 93 (21.4)
Nitrate 202 (46.6)
Diuretics 75 (17.3)
Spiranolactone 37 (8.5)
Fibrate 0 (0)
Statin 324 (74.8)
ata are expressed as mean± standard deviation, or number (percentage).
CE inhibitor, angiotensin-converting enzyme inhibitor; EES, everolimus-eluting stent; H
ensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol;Max.CK-MB,ma
ES, zotarolimus-eluting stent.ology 64 (2014) 273–278 275
Baseline clinical and laboratory characteristics and concomitant
medications
Baseline clinical and laboratory characteristics and concomitant
medications of the two groups are presented in Table 1. Patients
in the ZES group were older with lower heart rate, higher preva-
lence of family history of coronary artery disease, and higher serum
level of creatinine kinase-MB. Use of calcium-channel blockers and
ﬁbrates was less frequently observed in the ZES group compared to
that in the EES group.
Coronary angiographic and procedural characteristics
Coronary angiographic characteristics and procedural results
of the two groups are presented in Table 2. Patients in the ZES
group had higher pre-PCI TIMI grade 0 ﬂow, larger stent length,
and higher use of thrombus aspiration device compared to the EES
group. Other coronary angiographic characteristics did not show
statistically meaningful differences between the two groups.
Twelve-month clinical outcomesThe 12-month clinical outcomes are presented in Table 3. The
incidence of 12-month MACE was higher in the ZES group com-
pared to that in the EES group (5.7% vs 2.6%) and the incidence
EES p value
n=421
63.5±11.8 0.001
351 (83.3) 0.191
127.7±31.8 0.066
75.7±21.7 0.027
51.9±23.4 0.813
134 (31.8) 0.979
230 (54.6) 0.531
125 (29.7) 0.182
38 (0.09) 0.771
25 (5.9) 0.013
271 (64.4) 0.440
67 (1.6) 0.149
185.7±85.9 0.076
1.4±1.6 0.586
181.7±43.2 0.558
132.7±112.4 0.263
42.7±11.0 0.587
114.7±36.4 0.387
5.8±15.1 0.132
4226.1±7900.1 0.564
6.6±1.4 0.374
163.3±157.9 0.011
57.9±174.5 0.535
409 (97.1) 0. 997
410 (97.4) 0.998
113 (26.8) 0.696
26 (6.2) 0.005
359 (85.3) 0.062
272 (64.6) 0.059
87 (20.7) 0.652
185 (43.9) 0.490
77 (18.3) 0.738
30 (7.1) 0.485
4 (0.9) 0.042
309 (73.4) 0.290
bA1C, hemoglobin A1C; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-
ximumcreatine kinase-MB; NT-pro-BNP, N-terminal pro-brain natriuretic peptide;
276 K. Ahmed et al. / Journal of Cardi
Table 2
Coronary angiographic characteristics and procedural results.
Variable ZES EES p value
n=433 n=421
Intervened coronary artery
Left main 7 (1.6) 5 (1.2) 0.592
Left anterior descending 182 (42.0) 200 (47.5) 0.114
Left circumﬂex 41 (9.5) 44 (10.5) 0.639
Right coronary 201 (46.2) 171 (40.6) 0.082
Multi-vessel involvement 233 (53.8) 241 (57.3) 0.311
ACC/AHA lesion type C 188 (43.4) 180 (42.7) 0.877
Pre-TIMI grade 0 ﬂow 260(60.0) 217 (51.5) 0.020
Post-TIMI grade 3 ﬂow 1(0.23) 2 (0.5) 0.557
Total number of stents 1.4±0.7 1.5±0.7 0.112
Stent length (mm) 23.7±7.2 22.3±5.7 0.003
Stent diameter (mm) 3.2±0.5 3.2±0.4 0.333
Pre-PCI diameter stenosis (%) 91.4±13.8 90.6±15.3 0.581
Post-PCI diameter stenosis (%) 10.3±7.9 11.9±14.3 0.146
Intravascular ultrasound use 105 (24.3) 129 (30.6) 0.061
Glycoprotein IIb/IIIa inhibitor 67 (15.5) 65 (15.4) 0.989
Thrombus aspiration 179 (41.3) 129 (30.6) 0.001
PCI success rate 423 (97.7) 407 (96.7) 0.943
In-hospital complications 49 (11.3) 40 (9.5) 0.361
Data are expressed as mean± standard deviation or number (percentage).
ACC/AHA, American College of Cardiology/American Heart Association; EES,
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olysis In Myocardial Infarction; ZES, zotarolimus-eluting stent.
f all-cause death was higher in ZES with borderline signiﬁcance
ompared to EES (2.8% vs 0.9%). It is however noteworthy that
on-fatal MI, TVR, TLR, and stent thrombosis were not statistically
igniﬁcantly different between groups. A total of ﬁve cases of stent
hromboses developed of which two were sub-acute (one in ZES,
ne in EES) and three were late stent thromboses (two in ZES, one
n EES). The average rate of PCI success was 98.3%.
Kaplan–Meier survival analysis demonstrated insigniﬁcant dif-
erences in freedom from MACE and death between two groups
Fig. 1). Cox proportional hazard analysis revealed no statis-
ical differences in the incidence of MACE and death when
djusted for multiple confounders. MACE and all-cause death at
2 months did not differ signiﬁcantly between the two groups
espite propensity score adjustment using Cox model, p=0.326
or MACE, p=0.569 for death (Fig. 2). Subgroup analysis stratiﬁed
y eGFR below 30mL/min/1.73m2 or above 30mL/min/1.73m2
as performed. This was analyzed by using Cox regression model
djusted bypropensity score. The results are presented in the forest
lot as shown in Fig. 3. This did not show any signiﬁcant differ-
nces in 12-month MACE between ZES and EES either in eGFR
30mL/min/1.73m2 or <30mL/min/1.73m2 subgroups.
able 3
linical outcomes at 1 month and 12 months.
Outcome variable At 1 month
ZES EES p
n=432 n=419
Major adverse cardiac event 9 (2.1) 5 (1.2) 0
All-cause death 7 (1.6) 2 (0.5) 0
Cardiac death 5 (1.2) 0 (0) 0
Non-cardiac death 2 (0.5) 2 (0.5) 0
Non-fatal myocardial infarction 1 (0.2) 1 (0.2) 0
Repeat revascularization 1 (0.2) 2 (0.5) 0
Target vessel 0 (0) 0 (0) 0
Target lesion 0 (0) 0 (0) 0
Non-target vessel 1 (0.2) 2 (0.5) 0
Coronary artery bypass grafting 0 (0) 0 (0) 0
Stent thrombosis
ata are expressed as number (percentage).
ES, everolimus-eluting stent; ZES, zotarolimus-eluting stent.ology 64 (2014) 273–278
Discussion
The present study demonstrates that implantation of ZES or EES
provided comparable clinical outcomes with similar risk of 12-
month MACE and death in STEMI patients with CKD undergoing
primary PCI.
Most studies of cardiovascular outcomes have found that a
breakpoint for the development of contrast-induced nephropathy,
acute or subacute stent thrombosis, later restenosis, recur-
rent myocardial infarction, diastolic/systolic congestive heart
failure, and cardiovascular death occurs below an eGFR of
60mL/min/1.73m2, which roughly corresponds to a serum creati-
nine level higher than 1.5mg/dL in the general population [16–18].
A study by Bonello et al. [19] showed a graded increase in seri-
ous in-hospital complications (death, vascular complications, need
for transfusion, acute renal failure, MACE), 1-month events (death,
repeatMI, TLR,MACE), and 1-year outcomes (death,MI, TLR,MACE)
as renal function declined. In spite of these poor outcomes, use
of PCI is associated with superior long-term survival when com-
pared with medical therapy alone in the management of acute
coronary syndrome in CKD patients [20]. The frequency of clini-
cal adverse events was also higher according to the stages of CKD.
Hachinoheet al. [21] demonstratedwhenpatientswithnon-ST seg-
ment elevation MI have severe CKD, the conservative or deferred
invasive strategywith prescription of cardio-protectivemedication
and prevention of further deterioration in renal function should
be considered. They demonstrated that early invasive strategy was
superior to deferred invasive strategy in mild CKD patients. How-
ever, this tendency decreased as renal function decreased and
deferred strategy was superior to early invasive strategy in severe
CKD patients.
Although the use of new interventional devices, including
stents, improved immediate procedural success rates, CKDpatients
also had higher long-term mortality rates (27.7% versus 6.1%,
p<0.0001) than patientswith normal renal function [22]. There are
several leading explanations for CKD being such a potent risk fac-
tor for adverseoutcomes: (a) excess co-morbidities inCKDpatients,
including older age and diabetes; (b) underused end-organ protec-
tive strategies in CKD patients, or therapeutic nihilism; (c) excess
toxicities fromconventional therapiesused including radiocontrast
material and antithrombotic agents; and (d) the unique pathobiol-
ogy of the CKD state, which includes intrarenal vasoconstriction
when exposed to iodinated contrast agents [23].Coronary stents have substantially improved the efﬁcacy of per-
cutaneous revascularization. Use of DES has further reduced the
rates of in-stent restenosis and repeat revascularization compared
to BMS [24]. Despite thewidespread use of DES in treating coronary
At 12 months
value ZES EES p value
n=433 n=421
.305 25 (5.7) 11 (2.6) 0.022
.102 12 (2.8) 4 (0.9) 0.050
.027 6 (1.4) 1 (0.2) 0.063
.978 6 (1.4) 3 (0.7) 0.336
.984 1 (0.2) 1 (0.2) 0.984
.547 11 (2.5) 7 (1.7) 0.372
.999 4 (0.9) 1 (0.2) 0.189
.999 5 (1.2) 1 (0.2) 0.109
.547 2 (0.5) 5 (1.2) 0.240
.999 1 (0.2) 1 (0.2) 0.984
3 (0.7) 2 (0.5) 0.677
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Fig. 1. Kaplan–Meier curves for 12-monthMACEanddeath-free survival between the two commonly used stent types in patientswith acutemyocardial infarction and chronic
kidney disease undergoing primary percutaneous coronary intervention. EES, everolimus-eluting stent; MACE, major adverse cardiac event; ZES, zotarolimus-eluting stent.
Fig. 2. Propensity adjusted 12-month MACE and death-free survival between the two co
kidney disease undergoing primary percutaneous coronary intervention. MACE, major ad
Fig. 3. Estimates of hazard ratio (forest plot) for the primary end point (12-month
major adverse cardiac event) in subgroups eGFR >30mL/min/1.732m2 and eGFR
<30mL/min/1.732m2. CI, conﬁdence interval; EES, everolimus-eluting stent; eGFR,
estimated glomerular ﬁltration rate; ZES, zotarolimus-eluting stent.mmonly used stent types in patients with acute myocardial infarction and chronic
verse cardiac event.
artery disease which is prevalent among end-stage renal disease
patients, the safety and efﬁcacy of DES in this population have not
been well deﬁned. The overall results of a meta-analysis including
869 patients by Abdel-Latif et al. [25] indicate that DES use in these
patients is safe and results in a modest yet statistically signiﬁcant
reduction in adverse clinical events. Importantly, the procedural
success with DES was similar to that encountered with BMS. DES
use signiﬁcantly reduced the risk of TLR/TVR andMACE, but did not
signiﬁcantly inﬂuence the risk of all-cause mortality or MI.
A study by Serruys et al. [26] demonstrated that at 13 months,
the new-generation ZES was found to be non-inferior to the EES in
the general population. Our study showed that either of the two
commonly used stents can be used to treat AMI patients with CKD
(eGFR <60mL/min/1.73m2) undergoing primary PCI, with similar
risk of 12-month MACE. DESs have signiﬁcantly reduced rates of
restenosis compared to BMS, but an increased risk of late stent
thrombosis has emerged as a major concern [27]. However, we
observednosigniﬁcantbetween-groupdifference inoverall ratesof
stent thrombosis. Our observations may be inﬂuenced by selection
bias and residual confounding or may represent a true ﬁnding; it is
at least hypothesis-generating that needs to be further evaluated
using a long-term randomized controlled study.
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tudy limitations
The present study is limited due to its retrospective nature. We
id not study outcomes stratiﬁed by every stage of CKD and for
atients on dialysis. Patients did not undergo follow-up stress test
r coronary angiography; silent ischemia and restenosis could have
een under diagnosed. Information regarding renal function after
CI and details of scheduled angiographic follow-up were not col-
ected in the KAMIR. Follow-up renal function test after PCI to rule
ut acute kidney injury was not checked.
onclusions
Implantation of ZES or EES provided comparable clinical out-
omes with similar risk of 12-month MACE and death in STEMI
atients with CKD undergoing primary PCI.
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